Protein Misfolding Diseases

Erscheinungsjahr 2025
ISBN: 978-0-443-29414-3
Verlag: Elsevier Science & Technology

Buch, Englisch, Format (B × H): 152 mm x 229 mm

Protein Misfolding Diseases, delves into the intricate molecular mechanisms behind a class of devastating disorders caused by abnormal protein folding. This comprehensive book explores interesting and updated topics, including Protein misfolding in hemophilia, Characterizing Protein Misfolding: Inside and Out, Heat Shock proteins (HSPs) as chaperones for Oncogenesis, Protein Misfolding and Cancer: Molecular Insights and Future Perspectives, Proteostasis and Pathogenesis: Unraveling the Complexity of Protein Misfolding Disorders, Small molecule inhibitors targeting ?-synuclein aggregation: Progress and future outlook, and much more.

Additional sections cover Chaperone Machinery in Neurodegeneration: A Spotlight on Protein Misfolding Diseases and Calpain- mediated proteolytic cleavage.

Autoren/Hrsg.

Weitere Mitwirkende

Donev, Rossen

Bhat, Ajaz A.

Fachgebiete

• Naturwissenschaften Chemie Organische Chemie
• Naturwissenschaften Biowissenschaften Molekularbiologie
• Naturwissenschaften Physik Angewandte Physik Biophysik
• Naturwissenschaften Biowissenschaften Biochemie (nichtmedizinisch)

Inhaltsverzeichnis

1. Protein misfolding in hemophilia
Bilgimol Chumappumkal Joseph, Nicca Falah, Juan Andres De Pablo-Moreno, Dana H Simmons and Annette von Drygalski
2. TBD
Sarita Montaño
3. TBD
Sreejith Madhavankutty
4. Characterizing Protein Misfolding: Inside and Out
Amritangshu Chakravarty
5. TBD
Krishnamurthy Nakuluri and Vani Gowru
6. TBD
Shahab Uddin, Abdul Ansari, Aamir Ahmad, Lubna Therachiyil, Gazala Anamangadan, Manel Sadok and Hesham M Korashy
7. Longitudinal plasma proteome of vaccinated individuals reveals altered factors associated with blood coagulation and immune responses
Aamir Ahmad
8. TBD
Muzafar Ahmad Macha
9. TBD
Manzoor A. Mir Sr.
10. Heat Shock proteins (HSPs) as chaperones for Oncogenesis
Mayank Singh
11. TBD
Ajaz Ahmad Bhat
12. Protein Misfolding and Cancer: Molecular Insights and Future Perspectives
Sireesha V. Garimella and Geethika Ishani Makka
13. Proteostasis and Pathogenesis: Unraveling the Complexity of Protein Misfolding Disorders
Biplab Singha, Tripti Nair, Ditsa Sarkar, Sumit Murmu and Rahul Rawat
14. TBD
Surbhi Sharma
15. TBD
Rakesh Kumar I
16. Small molecule inhibitors targeting ?-synuclein aggregation: Progress and future outlook
Tanveer Ali Dar Sr., Ishfaq Bashir Hajam, Ishfaq Ahmad Ahanger and Umar Rasool
17. Chaperone Machinery in Neurodegeneration: A Spotlight on Protein Misfolding Diseases

Arpit Mehrotra, Abhilasha Sood, Deepak Kumar Sharma, Madhumita Dey and Arpit Tyagi
18. Title yet to decide
Shivani Mittal
19. Calpain- mediated proteolytic cleavage
Subashchandrabose Chinnathambi, Nagaraj Rangappa and Tushar Dubey

Über Autor(innen)

Donev, Rossen
Rossen Donev received his PhD degree in 1999 from the Institute of Molecular Biology, Bulgarian Academy of Sciences. He did postdoctoral training at Imperial Cancer Research Fund, UK (renamed after the merger with Cancer Research Campaign to Cancer Research UK, London Research Institute) and Cardiff University. In 2007 he was awarded a New Investigator Grant Award from the Medical Research Council (UK) to establish himself as an independent Principle Investigator. In 2010 Dr. Donev was appointed Senior Lecturer at Swansea University. In 2016 Dr. Donev joined MicroPharm Ltd (UK) where currently he is Head of Research. He has published more than 60 research papers, chaired scientific meetings and given invited plenary talks. Rossen Donev has consulted on projects related to development of treatments for neurodevelopmental disorders and cancer therapies. He serves as Editor-in-Chief of the Advances in Protein Chemistry and Structural Biology and on editorial board of several other journals. His research interests include signaling pathways involved in neuropsychiatric disorders and tumor escape from the immune system, and development of therapeutic strategies for their treatment. More recently he has focused on development of immunotherapeutics for non-systemic applications.